Swedish Orphan ADR (SWTUY) 16.9470 $SWTUY
Idiopathic Juvenile Arthritis (Still's Disease) Therapeutics Pipeline Review 2015
M2 - Wed May 06, 8:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vkzw3z/idiopathic) has announced the addition of the "Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlphaMab Co., Ltd - Biocon Limited - Epirus Biopharmaceuticals, Inc. - Genor BioPharma Co., Ltd. - Mabion SA - Oncodesign SA - Panacea Biotec Limited - Pfizer Inc. - Sandoz International GmbH - Swedish Orphan Biovitrum AB - UCB S.A. For more information visit http://www.researchandmarkets.com/research/vkzw3z/idiopathic
PFE: 33.98 (-0.01)
Sobi publishes its Report for the First Quarter 2015
Thomson Reuters ONE - Wed May 06, 1:33AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the first quarter 2015. Revenues for the quarter totalled SEK 865 M (573). All parts of the business contributed to the result with ReFacto(R), Orfadin(R) and Kineret(R) delivering strong performance.
Early treatment and a longer life - new Orfadin formats meet new patient needs
Thomson Reuters ONE - Mon May 04, 7:31AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the oral suspension formulation and the 20 mg capsule of Orfadin (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1). HT-1 is a rare genetic disease that affects infants and children; it is progressive in nature, may result in liver and kidney failure and can be fatal if untreated.
Invitation - Presentation of Sobi's first quarter 2015
Thomson Reuters ONE - Thu Apr 30, 1:00AM CDT
On 6 May, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the first quarter 2015.
Sobi's Board of Directors postpones Annual General Meeting of Shareholders
Thomson Reuters ONE - Wed Apr 29, 1:06AM CDT
On 27 April 2015 the Board of Directors of Swedish Orphan Biovitrum AB (publ) (Sobi) confirmed that it had received a preliminary and conditional non-binding proposal in relation to a possible offer for all shares issued by the company. There can be no certainty that an offer will be made, nor as to the terms of any such offer.
Statement regarding recent speculation
Thomson Reuters ONE - Mon Apr 27, 1:06AM CDT
The Board of Swedish Orphan Biovitrum AB (publ) notes the recent speculation in the press and elsewhere regarding a potential acquisition of the company.
Swedish Orphan Biovitrum AB (publ) : Sobi publishes Annual Report 2014
Thomson Reuters ONE - Wed Apr 15, 6:01AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today published its Annual Report for 2014, themed "We have a story to tell", on the company's website, www.sobi.com.
Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)
Thomson Reuters ONE - Mon Mar 30, 1:01AM CDT
The shareholders in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, are hereby summoned to the annual general meeting (the "Meeting"
, to be held on Wednesday 6 May 2015 at 4.00 p.m. in Wallenbergaren, at Naringslivets hus, Storgatan 19, Stockholm, Sweden.
Sobi publishes its Report for the Fourth Quarter and Full Year 2014
Thomson Reuters ONE - Thu Feb 19, 1:02AM CST
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the fourth quarter and full year 2014. Revenues for the year totalled SEK 2,607 M (2,177), an increase of 20 per cent. Revenues in the fourth quarter were 15 per cent higher compared to the previous year. All parts of the business contributed to the result with Orfadin(R) and the Partner Products portfolio delivering strong performance.
Invitation - Presentation of Sobi's fourth quarter and full year results 2014
Thomson Reuters ONE - Thu Feb 12, 1:00AM CST
On 19 February, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the fourth quarter and full year 2014.
BioSpecifics Technologies wins approval for XIAPEX in the EU for treating Peyronie's Disease
M2 - Tue Feb 03, 5:16AM CST
Biopharmaceutical company BioSpecifics Technologies (NasdaqGM:BSTC) reported on Monday the receipt of approval by the Swedish Orphan Biovitrum AB (Sobi) from the EU Commission to market XIAPEX for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees.
BSTC: 37.97 (-0.12)
Exelixis and Swedish Orphan Biovitrum AB (Sobi) Extend and Restructure Distribution Agreement for COMETRIQ(R) for Medullary Thyroid Cancer
Business Wire - Wed Jan 07, 7:30AM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced that it has extended and restructured its agreement with Swedish Orphan Biovitrum AB (Sobi) to support the distribution and commercialization of COMETRIQ(R) (cabozantinib) for progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC) in the European Union (EU), Switzerland, Norway, Russia, and Turkey. The agreement, which was established in February 2013 and due to expire on December 31, 2015, will now extend to December 31, 2019. Moreover, the payment structure of the partnership will transition from fixed fees paid by Exelixis to Sobi to support initial build out of COMETRIQ European commercial infrastructure to a sales margin-based approach. Exelixis continues to maintain commercial rights for all other potential cabozantinib oncology indications on a global basis.
EXEL: 3.34 (-0.03)
Sobi awarded CHMP's positive opinion for Xiapex for the treatment of Peyronie's disease
M2 - Tue Dec 23, 5:37AM CST
Healthcare company Swedish Orphan Biovitrum AB (Sobi) and partner Auxilium Pharmaceuticals on Monday jointly announced the receipt of positive opinion for Xiapex for treating adult men with Peyronie's disease, a condition that involves the development of collagen plaque, or scar tissue, on the shaft of the penis.
AUXL: 36.47 (-0.06)
Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease
PR Newswire - Mon Dec 22, 6:00AM CST
Swedish Orphan Biovitrum AB (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of Xiapex® (collagenase clostridium histolyticum) for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.
AUXL: 36.47 (-0.06)
Sobi's 2011 Long-Term incentive Programme meets all objectives
Thomson Reuters ONE - Fri Dec 19, 1:00AM CST
Swedish Orphan Biovitrum AB's (publ) (Sobi) Board of Directors today announced that the company's 2011 Long-Term Incentive programme met its objectives set and has vested in full. The total number of shares awarded to Sobi employees enrolled in the 2011 programme is 514 808.
Sobi CEO Geoffrey McDonough sells a portion of 2014 incentive shares
Thomson Reuters ONE - Tue Dec 09, 7:16AM CST
During the first week of December 2014 Sobi's CEO Geoffrey McDonough sold 350,000 of the shares he holds in Sobi. The sale was made in order to cover the estimated US tax liability for both the company's CEO incentive share programme, which vested in September 2014, and for the vesting in mid-December 2014 of the company's 2011 long-term incentive programme. This is the first time during his employment at Sobi that the CEO has been awarded shares under the incentive programmes.
Sobi exercises opt-in right for Elocta(TM)
Thomson Reuters ONE - Fri Nov 21, 1:01AM CST
Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) announced today that the company has decided to exercise its opt-in right to take over final development and commercialisation of Elocta (rFVIIIFc) for the territory composed of Europe, North Africa, Russia and most Middle Eastern markets. Elocta/Eloctate(TM) is a recombinant factor VIII Fc fusion protein product candidate for the treatment of haemophilia A. Sobi will make a payment to Biogen Idec of USD 10 million, which will be held in escrow pending the EU regulatory approval of Elocta. Details about this and other compensation are described in the Collaboration Agreement section below.
BIIB: 395.42 (+4.18)
Biogen Idec and Sobi announce European Medicines Agency validates Elocta(TM) (rFVIIIFc) Marketing Authorisation Application for review
Thomson Reuters ONE - Fri Oct 31, 3:10PM CDT
Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) of Elocta(TM) (rFVIIIFc), a recombinant factor VIII Fc fusion protein product candidate for the treatment of haemophilia A. The validation of the MAA initiates the EMA's review process.
BIIB: 395.42 (+4.18)
Sobi publishes Report for the Third Quarter 2014
Thomson Reuters ONE - Thu Oct 30, 2:01AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today its results for the third quarter 2014. Revenue totalled SEK 666 M (517), an increase of 29 per cent with contribution from all areas of the portfolio. Product revenues excluding income from Manufacturing and Royalty from ReFacto grew 35 per cent to SEK 532 M.
Idiopathic Juvenile Arthritis (Still's Disease) Therapeutics Pipeline Review 2015
M2 - Wed May 06, 8:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vkzw3z/idiopathic) has announced the addition of the "Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlphaMab Co., Ltd - Biocon Limited - Epirus Biopharmaceuticals, Inc. - Genor BioPharma Co., Ltd. - Mabion SA - Oncodesign SA - Panacea Biotec Limited - Pfizer Inc. - Sandoz International GmbH - Swedish Orphan Biovitrum AB - UCB S.A. For more information visit http://www.researchandmarkets.com/research/vkzw3z/idiopathic
PFE: 33.98 (-0.01)
Sobi publishes its Report for the First Quarter 2015
Thomson Reuters ONE - Wed May 06, 1:33AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the first quarter 2015. Revenues for the quarter totalled SEK 865 M (573). All parts of the business contributed to the result with ReFacto(R), Orfadin(R) and Kineret(R) delivering strong performance.
Early treatment and a longer life - new Orfadin formats meet new patient needs
Thomson Reuters ONE - Mon May 04, 7:31AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the oral suspension formulation and the 20 mg capsule of Orfadin (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1). HT-1 is a rare genetic disease that affects infants and children; it is progressive in nature, may result in liver and kidney failure and can be fatal if untreated.
Invitation - Presentation of Sobi's first quarter 2015
Thomson Reuters ONE - Thu Apr 30, 1:00AM CDT
On 6 May, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the first quarter 2015.
Sobi's Board of Directors postpones Annual General Meeting of Shareholders
Thomson Reuters ONE - Wed Apr 29, 1:06AM CDT
On 27 April 2015 the Board of Directors of Swedish Orphan Biovitrum AB (publ) (Sobi) confirmed that it had received a preliminary and conditional non-binding proposal in relation to a possible offer for all shares issued by the company. There can be no certainty that an offer will be made, nor as to the terms of any such offer.
Statement regarding recent speculation
Thomson Reuters ONE - Mon Apr 27, 1:06AM CDT
The Board of Swedish Orphan Biovitrum AB (publ) notes the recent speculation in the press and elsewhere regarding a potential acquisition of the company.
Swedish Orphan Biovitrum AB (publ) : Sobi publishes Annual Report 2014
Thomson Reuters ONE - Wed Apr 15, 6:01AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today published its Annual Report for 2014, themed "We have a story to tell", on the company's website, www.sobi.com.
Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)
Thomson Reuters ONE - Mon Mar 30, 1:01AM CDT
The shareholders in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, are hereby summoned to the annual general meeting (the "Meeting"
, to be held on Wednesday 6 May 2015 at 4.00 p.m. in Wallenbergaren, at Naringslivets hus, Storgatan 19, Stockholm, Sweden. Sobi publishes its Report for the Fourth Quarter and Full Year 2014
Thomson Reuters ONE - Thu Feb 19, 1:02AM CST
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the fourth quarter and full year 2014. Revenues for the year totalled SEK 2,607 M (2,177), an increase of 20 per cent. Revenues in the fourth quarter were 15 per cent higher compared to the previous year. All parts of the business contributed to the result with Orfadin(R) and the Partner Products portfolio delivering strong performance.
Invitation - Presentation of Sobi's fourth quarter and full year results 2014
Thomson Reuters ONE - Thu Feb 12, 1:00AM CST
On 19 February, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the fourth quarter and full year 2014.
BioSpecifics Technologies wins approval for XIAPEX in the EU for treating Peyronie's Disease
M2 - Tue Feb 03, 5:16AM CST
Biopharmaceutical company BioSpecifics Technologies (NasdaqGM:BSTC) reported on Monday the receipt of approval by the Swedish Orphan Biovitrum AB (Sobi) from the EU Commission to market XIAPEX for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees.
BSTC: 37.97 (-0.12)
Exelixis and Swedish Orphan Biovitrum AB (Sobi) Extend and Restructure Distribution Agreement for COMETRIQ(R) for Medullary Thyroid Cancer
Business Wire - Wed Jan 07, 7:30AM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced that it has extended and restructured its agreement with Swedish Orphan Biovitrum AB (Sobi) to support the distribution and commercialization of COMETRIQ(R) (cabozantinib) for progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC) in the European Union (EU), Switzerland, Norway, Russia, and Turkey. The agreement, which was established in February 2013 and due to expire on December 31, 2015, will now extend to December 31, 2019. Moreover, the payment structure of the partnership will transition from fixed fees paid by Exelixis to Sobi to support initial build out of COMETRIQ European commercial infrastructure to a sales margin-based approach. Exelixis continues to maintain commercial rights for all other potential cabozantinib oncology indications on a global basis.
EXEL: 3.34 (-0.03)
Sobi awarded CHMP's positive opinion for Xiapex for the treatment of Peyronie's disease
M2 - Tue Dec 23, 5:37AM CST
Healthcare company Swedish Orphan Biovitrum AB (Sobi) and partner Auxilium Pharmaceuticals on Monday jointly announced the receipt of positive opinion for Xiapex for treating adult men with Peyronie's disease, a condition that involves the development of collagen plaque, or scar tissue, on the shaft of the penis.
AUXL: 36.47 (-0.06)
Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease
PR Newswire - Mon Dec 22, 6:00AM CST
Swedish Orphan Biovitrum AB (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of Xiapex® (collagenase clostridium histolyticum) for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.
AUXL: 36.47 (-0.06)
Sobi's 2011 Long-Term incentive Programme meets all objectives
Thomson Reuters ONE - Fri Dec 19, 1:00AM CST
Swedish Orphan Biovitrum AB's (publ) (Sobi) Board of Directors today announced that the company's 2011 Long-Term Incentive programme met its objectives set and has vested in full. The total number of shares awarded to Sobi employees enrolled in the 2011 programme is 514 808.
Sobi CEO Geoffrey McDonough sells a portion of 2014 incentive shares
Thomson Reuters ONE - Tue Dec 09, 7:16AM CST
During the first week of December 2014 Sobi's CEO Geoffrey McDonough sold 350,000 of the shares he holds in Sobi. The sale was made in order to cover the estimated US tax liability for both the company's CEO incentive share programme, which vested in September 2014, and for the vesting in mid-December 2014 of the company's 2011 long-term incentive programme. This is the first time during his employment at Sobi that the CEO has been awarded shares under the incentive programmes.
Sobi exercises opt-in right for Elocta(TM)
Thomson Reuters ONE - Fri Nov 21, 1:01AM CST
Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) announced today that the company has decided to exercise its opt-in right to take over final development and commercialisation of Elocta (rFVIIIFc) for the territory composed of Europe, North Africa, Russia and most Middle Eastern markets. Elocta/Eloctate(TM) is a recombinant factor VIII Fc fusion protein product candidate for the treatment of haemophilia A. Sobi will make a payment to Biogen Idec of USD 10 million, which will be held in escrow pending the EU regulatory approval of Elocta. Details about this and other compensation are described in the Collaboration Agreement section below.
BIIB: 395.42 (+4.18)
Biogen Idec and Sobi announce European Medicines Agency validates Elocta(TM) (rFVIIIFc) Marketing Authorisation Application for review
Thomson Reuters ONE - Fri Oct 31, 3:10PM CDT
Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) of Elocta(TM) (rFVIIIFc), a recombinant factor VIII Fc fusion protein product candidate for the treatment of haemophilia A. The validation of the MAA initiates the EMA's review process.
BIIB: 395.42 (+4.18)
Sobi publishes Report for the Third Quarter 2014
Thomson Reuters ONE - Thu Oct 30, 2:01AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today its results for the third quarter 2014. Revenue totalled SEK 666 M (517), an increase of 29 per cent with contribution from all areas of the portfolio. Product revenues excluding income from Manufacturing and Royalty from ReFacto grew 35 per cent to SEK 532 M.
